News | November 07, 2012

Low Levels of Anti-PC Predict Vein Graft Failure

November 7, 2012 — Athera Biotechnologies AB announced that results from a new study were presented at the Pacific Northwest Vascular Society Annual Meeting in Vancouver, Canada. The data shows that low levels of plasma anti-PC, measured with Athera’s CVDefine kit, are associated with a high risk for vein graft failure after bypass surgery.

It is known from previous published studies that low plasma levels of antibodies against phosphorylcholine (anti-PC) are linked to poor prognosis in acute heart attack patients, as well as to development of atherosclerosis and serious cardiovascular consequences like heart attack and stroke in healthy individuals. Michael Sobel, division of vascular surgery, VA Puget Sound HCS, and the University of Washington, Seattle, and his colleagues have now conducted a pilot, prospective, observational study in patients undergoing vein bypasses for atherosclerotic occlusive disease of the legs. The objective of the study was to determine if low anti-PC antibody levels might be associated with loss of primary patency. Measurements of anti-PC levels in these patients, using a simple blood test, showed that low levels were associated with a high risk of thrombosis or re-intervention for stenosis, also raising the possibility of treatment with immunotherapies to improve bypass longevity. The testing was performed using Athera’s CVDefine kit.

More than one in four of all vein graft procedures develop stenosis or fail within the first one to two years. These patients are at risk for re-intervention, as well as more serious complications like leg amputation or death. Current treatments to improve graft longevity are limited to general medical treatments (e.g., antithrombotic drugs and lipid lowering agents) or procedures to revise the graft, but no targeted treatments are approved yet.

“Athera is developing an anti-inflammatory antibody therapy, PC-mAb, for prevention of secondary cardiovascular events in myocardial infarction patients with low levels of anti-PC. These new findings may open opportunities for PC-mAb and its companion diagnostic kit CVDefine, for identification and treatment of a high-risk patient group in a niche indication of high medical need,” said Carina Schmidt, CEO of Athera.

For more information: www.athera.se

Related Content

Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Societies Issue New Performance and Quality Measures for Treating Patients with Heart Attack
News | Cath Lab| October 17, 2017
The American College of Cardiology and the American Heart Association recently released updated clinical performance...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
Overlay Init